Skip to main content
Top
Published in: Rheumatology International 3/2014

01-03-2014 | Short Communication

Clinical symptoms in fibromyalgia are associated to overweight and lipid profile

Authors: Mario D. Cordero, Elísabet Alcocer-Gómez, Francisco J. Cano-García, Benito Sánchez-Domínguez, Patricia Fernández-Riejo, Ana M. Moreno Fernández, Ana Fernández-Rodríguez, Manuel De Miguel

Published in: Rheumatology International | Issue 3/2014

Login to get access

Abstract

In order to analyze the association between body mass index (BMI), lipid profile and clinical symptoms in patients with fibromyalgia, we assessed BMI levels, lipid profile and its association with clinical symptoms in 183 patients with fibromyalgia. The patients were evaluated using tender points, FIQ and Visual Analogue Scales of pain (VAS). Serum lipid profile analysis (total cholesterol, triglyceride, HDL, LDL and VLDL), and biochemical parameters were measured in the biochemistry laboratory. The BMI distribution of the nonobese, overweight and obese patients’ groups were relatively even with 37.7, 35.5 and 26.8 %, respectively, with a mean BMI of 27.3 ± 4.9. The number of tender points showed significantly positive correlation with higher BMI (P < 0.05). A total of 57.9 % of patients showed increased levels of total cholesterol, 63.4 % increased levels of LDL cholesterol and 19.9 % high levels of triglycerides. BMI, total cholesterol and triglycerides showed high association with some clinical parameters. Overweight and lipid profile could be associated with fibromyalgia symptoms. A treatment program with weight loss strategies, and control in diet and increased physical activity is advised to patients.
Literature
1.
go back to reference Lawrence RC, Helmick CG, Arnett FC et al (1998) Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 41:778–799PubMedCrossRef Lawrence RC, Helmick CG, Arnett FC et al (1998) Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 41:778–799PubMedCrossRef
2.
go back to reference Wolfe F, Smythe HA, Yunus MB et al (1990) The American college of rheumatology 1990 criteria for the classification of fibromyalgia. Report of the multicenter criteria committee. Arthritis Rheum 33:160–172PubMedCrossRef Wolfe F, Smythe HA, Yunus MB et al (1990) The American college of rheumatology 1990 criteria for the classification of fibromyalgia. Report of the multicenter criteria committee. Arthritis Rheum 33:160–172PubMedCrossRef
3.
go back to reference Pillemer SR (1994) The fibromyalgia syndrome: current research and future directions in epidemiology pathogenesis and treatment NIH conference. J Musculoskeletal Pain 2:113–115CrossRef Pillemer SR (1994) The fibromyalgia syndrome: current research and future directions in epidemiology pathogenesis and treatment NIH conference. J Musculoskeletal Pain 2:113–115CrossRef
4.
go back to reference Neumann L, Lerner E, Glazer Y et al (2008) A cross-sectional study of the relationship between body mass index and clinical characteristics, tenderness measures, quality of life, and physical functioning in fibromyalgia patients. Clin Rheumatol 27:1543–1547PubMedCrossRef Neumann L, Lerner E, Glazer Y et al (2008) A cross-sectional study of the relationship between body mass index and clinical characteristics, tenderness measures, quality of life, and physical functioning in fibromyalgia patients. Clin Rheumatol 27:1543–1547PubMedCrossRef
5.
6.
go back to reference Arranz L, Canela MA, Rafecas M (2011) Relationship between body mass index, fat mass and lean mass with SF-36 quality of life scores in a group of fibromyalgia patients. Rheumatol Int. doi:10.1007/s00296-011-2250-y Arranz L, Canela MA, Rafecas M (2011) Relationship between body mass index, fat mass and lean mass with SF-36 quality of life scores in a group of fibromyalgia patients. Rheumatol Int. doi:10.​1007/​s00296-011-2250-y
7.
go back to reference Yunus MB, Arslan S, Aldag JC (2002) Relationship between body mass index and fibromyalgia features. Scand J Rheumatol 31:27–31PubMedCrossRef Yunus MB, Arslan S, Aldag JC (2002) Relationship between body mass index and fibromyalgia features. Scand J Rheumatol 31:27–31PubMedCrossRef
8.
go back to reference Mengshoel AM, Haugen M (2001) Health status in fibromyalgia a followup study. J Rheumatol 28:2085–2089PubMed Mengshoel AM, Haugen M (2001) Health status in fibromyalgia a followup study. J Rheumatol 28:2085–2089PubMed
9.
go back to reference Loevinger BL, Muller D, Alonso C, Coe CL (2007) Metabolic syndrome in women with chronic pain. Metabolism 56:87–93PubMedCrossRef Loevinger BL, Muller D, Alonso C, Coe CL (2007) Metabolic syndrome in women with chronic pain. Metabolism 56:87–93PubMedCrossRef
10.
go back to reference Gurer G, Sendur OF, Ay C (2006) Serum lipid profile in fibromyalgia women. Clin Rheumatol 25:300–303PubMedCrossRef Gurer G, Sendur OF, Ay C (2006) Serum lipid profile in fibromyalgia women. Clin Rheumatol 25:300–303PubMedCrossRef
11.
go back to reference Ozgocmen S, Ardicoglu O (2000) Lipid profile in patients with fibromyalgia and myofascial pain syndromes. Yonsei Med J 41:541–545PubMed Ozgocmen S, Ardicoglu O (2000) Lipid profile in patients with fibromyalgia and myofascial pain syndromes. Yonsei Med J 41:541–545PubMed
12.
go back to reference Morris SJ, Wasko MC, Antohe JL et al (2011) Hydroxychloroquine use associated with improvement in lipid profiles in rheumatoid arthritis patients. Arthritis Care Res (Hoboken) 63:530–534CrossRef Morris SJ, Wasko MC, Antohe JL et al (2011) Hydroxychloroquine use associated with improvement in lipid profiles in rheumatoid arthritis patients. Arthritis Care Res (Hoboken) 63:530–534CrossRef
13.
go back to reference Mok CC, Ko GT, Ho LY et al (2011) Prevalence of atherosclerotic risk factors and the metabolic syndrome in patients with chronic inflammatory arthritis. Arthritis Care Res (Hoboken) 63:195–202CrossRef Mok CC, Ko GT, Ho LY et al (2011) Prevalence of atherosclerotic risk factors and the metabolic syndrome in patients with chronic inflammatory arthritis. Arthritis Care Res (Hoboken) 63:195–202CrossRef
14.
go back to reference Obesity: preventing and managing the global epidemic (2000). Report of a WHO consultation. World Health Organ Tech Rep Ser 894:1–12, 1–253 Obesity: preventing and managing the global epidemic (2000). Report of a WHO consultation. World Health Organ Tech Rep Ser 894:1–12, 1–253
15.
go back to reference Bingfors K, Isacson D (2004) Epidemiology, co-morbidity, and impact on health-related quality of life of self-reported headache and musculoskeletal pain—a gender perspective. Eur J Pain 8:435–450CrossRef Bingfors K, Isacson D (2004) Epidemiology, co-morbidity, and impact on health-related quality of life of self-reported headache and musculoskeletal pain—a gender perspective. Eur J Pain 8:435–450CrossRef
17.
go back to reference Okifuji A, Bradshaw DH, Olson C (2009) Evaluating obesity in fibromyalgia: neuroendocrine biomarkers, symptoms, and functions. Clin Rheumatol 28:475–478PubMedCentralPubMedCrossRef Okifuji A, Bradshaw DH, Olson C (2009) Evaluating obesity in fibromyalgia: neuroendocrine biomarkers, symptoms, and functions. Clin Rheumatol 28:475–478PubMedCentralPubMedCrossRef
18.
go back to reference Okifuji A, Donaldson GW, Barck L, Fine PG (2010) Relationship between fibromyalgia and obesity in pain, function, mood, and sleep. J Pain 11:1329–1337PubMedCentralPubMedCrossRef Okifuji A, Donaldson GW, Barck L, Fine PG (2010) Relationship between fibromyalgia and obesity in pain, function, mood, and sleep. J Pain 11:1329–1337PubMedCentralPubMedCrossRef
19.
go back to reference Saggini A, Anogeianaki A, Maccauro G et al (2011) Cholesterol, cytokines and diseases. Int J Immunopathol Pharmacol 24:567–581PubMed Saggini A, Anogeianaki A, Maccauro G et al (2011) Cholesterol, cytokines and diseases. Int J Immunopathol Pharmacol 24:567–581PubMed
20.
go back to reference Klemp P, Halland AM, Majoos FL, Steyn K (1993) Musculoskeletal manifestations in hyperlipidaemia: a controlled study. Ann Rheum Dis 52:44–48PubMedCrossRef Klemp P, Halland AM, Majoos FL, Steyn K (1993) Musculoskeletal manifestations in hyperlipidaemia: a controlled study. Ann Rheum Dis 52:44–48PubMedCrossRef
Metadata
Title
Clinical symptoms in fibromyalgia are associated to overweight and lipid profile
Authors
Mario D. Cordero
Elísabet Alcocer-Gómez
Francisco J. Cano-García
Benito Sánchez-Domínguez
Patricia Fernández-Riejo
Ana M. Moreno Fernández
Ana Fernández-Rodríguez
Manuel De Miguel
Publication date
01-03-2014
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 3/2014
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-012-2647-2

Other articles of this Issue 3/2014

Rheumatology International 3/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine